In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function. Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat. Sprague-Dawley rats were randomized to either sham or ACF Ϯ allopurinol (100 mg·kg Ϫ1 ·day Ϫ1 , n Ն7 rats/group). Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P Ͻ 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P Ͻ 0.05), and a twofold increase in lung weight (P Ͻ 0.05) in treated and untreated ACF groups versus the sham group. LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF ϩ allopurinol rats, all of which occurred in the absence of changes in the maximum O 2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer. However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight. In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca 2ϩ sensitivity. However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure. heart failure; volume overload; xanthine oxidase; mitochondria A PURE VOLUME OVERLOAD (VO), without an increase in systolic pressure, increases diastolic load and results in an adverse eccentric left ventricular (LV) hypertrophy and remodeling manifested by wall thinning, cardiomyocyte elongation, and a decrease in the LV mass to volume.
A PURE VOLUME OVERLOAD (VO), without an increase in systolic pressure, increases diastolic load and results in an adverse eccentric left ventricular (LV) hypertrophy and remodeling manifested by wall thinning, cardiomyocyte elongation, and a decrease in the LV mass to volume.
Currently, there is no medical therapy to attenuate this remodeling process and progression to heart failure (10) . Recently, our laboratory has demonstrated increased cardiomyocyte oxidative stress in patients with VO of isolated chronic mitral regurgitation (1) and in rats with VO of aortocaval fistula (ACF) (18, 39) . Specifically, xanthine oxidase (XO) is elevated in cardiomyocytes along with myofibrillar degeneration and mitochondrial dysfunction and damage, despite a preserved LV ejection fraction (LVEF). The preservation of LV shortening has been shown to belie underlying cardiomyocyte dysfunction due to ejection into the low pressure left atrium and, in this animal model, ejection into the aortovenous fistula. XO is a critical mediator of ATP and purine degradation and produces ROS when O 2 is used as an electron acceptor during purine metabolism (30) . We have postulated that increased myocardial O 2 demand in the volume-overloaded heart with increased XO activity and ATP turnover sets up a vicious cycle of ROS production that can negatively impact multiple processes in the cardiomyocyte by altering mitochondrial function and production of ROS that impact other sensitive protein targets (18) .
To gain further insight into the intracellular biochemical consequences of VO, we have shown that cyclical stretch of adult rat cardiomyocytes increases XO activity and results in mitochondrial swelling, disorganization, and myofibrillar degeneration that is similar to the changes identified in the human LV with isolated mitral regurgitation (1, 18) . Treatment of stretched cardiomyocytes with allopurinol or the mitochondria-targeted antioxidant drug MitoQ prevents myofibrillar degeneration, mitochondrial damage, and the increase in XO activity (18) . XO inhibition during 24 h of ACF normalizes the depression of maximum O 2 consumption in isolated subsarcolemmal mitochondria and siginficantly improves LV contractility compared with untreated ACF rats (18) .
These studies have indicated that XO activation from hemodynamic stress of stretch/VO induces cardiomyocyte oxidative stress that may be central to bioenergetic dysfunction in acute VO. Alternatively, the improvement of LV contractility may be related to an effect of oxidative stress on cardiomyocyte Ca 2ϩ homestasis and/or oxidative modification of other myofibrillar and nonmitochondrial enzymatic proteins (8, 17, 34) . XO inhibition has been shown to ameliorate maladaptive alterations of Ca 2ϩ cycling proteins and improve LV function in repsonse to ␤-adrenergic stimulation in the dog after 4 wk of tachypacing (34) . Recently, ROS production from XO has been linked to myocardial high-energy phosphates and ATP flux through creatine kinase in the failing human heart (26). Treatment of heart failure patients with an XO inhibitor increases the phosphocreatine-to-ATP ratio and creatine kinase flux, as measured using in vivo 31 P magnetic resonance spectroscopy, which is consistent with the high susceptibility of creatine kinase to oxidative modifications resulting in decreased activity and efficiency of high-energy phosphate transfer from mitochondria to the contractile apparatus (26) .
Despite the many documented beneficial effects of XO inhibiton in different animal models of heart failure (30), the single clinical trial of oxypurinol in patients with class III-IV heart failure reported no beneficial effect on composite clinical endpoints in patients with New York Heart Association class III-IV heart failure (23). However, the efficacy of XO inhibition has not been tested in the pathogenesis of a pure VO. Here, we studied chronic VO of ACF in the rat and attempted to determine whether XO inhibition has a long-term beneficial effect on LV remodeling/function and cardiomyocyte bioenergetics using the extracellular flux (XF24) analyzer from Seahorse Bioscience, which allows for quantitative real-time measurements of O 2 consumption and pH in cardiomyocyte culture (14, 24, 25, 32) .
MATERIALS AND METHODS
Animal preparation. Sprague-Dawley rats (200 -250g) at 12 wk of age were subjected to either to sham or ACF, as previously described by our laboratory (18, 33, 39, 40) , with and without the XO inhibitor allopurinol (100 mg/kg, Sigma) for 8 wk. Allopurinol was started at the time of surgery and delivered in standard rat chow. Separate sets of sham and ACF rats were euthanized 8 wk after surgery for experiments using isolated cardiomyocytes in the extracellular flux analyzer (n ϭ 6 rats/group) and heart mitochondria (n ϭ 6 rats/group). Another set of sham and ACF rats was studied for in vivo hemodynamic and echo measurements before death, and this tissue was used for protein analysis (n ϭ 5 rats/group). This study was approved by the Animal Resource Program of the University of Alabama at Birmingham (Birmingham, AL).
Hemodynamics and echocardiography. Echocardiography and hemodynamics were performed before death using the Visualsonics imaging system (Vivo 770, Toronto, Ontario, Canada) combined with simultaneous high-fidelity LV pressure catheter recordings (Millar Instruments, Houston, TX). With the rat under isoflurane anesthesia, a high-fidelity LV pressure catheter was advanced into the LV cavity via a right carotid cut down. LV pressure and echocardiography dimensions (wall thickness and chamber diameter) were obtained simultaneously using software included in the Visualsonics system. LV volume was calculated from traced M-mode LV dimensions using the following Teicholz formula:
where V is volume and LVID is the LV internal dimension.
LV wall stress was calculated from traced M-mode LV dimensions and simultaneous LV pressure data using the following equation:
where LV is LV wall stress, LVP is LV pressure, r is the LV chamber radius, and LVwt is LV wall thickness. These LV pressurevolume data were analyzed for LV pressure-volume area and stroke work using the Labscribe2 software package (iWorx System Dover, NH).
Isolation of LV cardiomyocytes. Cardiomyocytes were isolated from sham and ACF rats, as previously described by our laboratory (18, 33, 39) . Briefly, hearts were perfused with perfusion buffer (120 mmol/l NaCl, 15 mmol/l KCl, 0.5 mmol/l KH 2PO4, 5 mmol/l NaHCO3, 10 mmol/l HEPES, and 5 mmol/l glucose at pH 7.0) for 5 min and digested with perfusion buffer containing 2% collagenase type II (Invitrogen, Carlsbad, CA) for 30 min at 37°C. The right ventricle, atria, and apex were removed before the perfused heart was minced. The digestion was filtered and washed, and cells were pelleted. Only samples with purity and viability (rod-shaped cells) fo Ͼ95% or 80%, respectively, were used.
Cellular bioenergetics. To determine the effects of VO and treatment with allopurinol on cellular bioenergetics, the Seahorse Bioscience XF24 extracellular flux analyzer was used to measure the O 2 consumption of adult cardiomyocytes in culture. Real-time, noninvasive measurements of O 2 consumption were determined using fluorescent probes adhered to disposable assay cartridges. These measurements were used to correlate the O2 consumption rate (OCR) to mitochondrial function. Primary adult rat cardiomyocytes were attached to specialized V28 plates (Seahorse Bioscience) coated with laminin at 7,500 cells/well. Cells were then allowed to attach for 2 h, after which the culture media were changed to unbuffered DMEM supplemented with 1% FBS, 4 mM L-glutamine, and 5 mM glucose for the XF24 assays.
Parameters of mitochondrial function were measured using the ability of the XF24 to inject compounds into the wells through an assay, as previously described (14, 24) . Briefly, the basal O 2 consumption of the cardiomyocytes was determined by measuring the OCR of the cells over time without any treatment. Next, FCCP (1 M) was injected to stimulate the maximal OCR of the cells. Finally, antimycin A (10 M) and rotenone (1 M) were injected simultaneously to completely inhibit the mitochondrial electron transport chain, thus yielding the nonmitochondrial OCR of the cardiomyocytes. The amount of cardiomyocytes plated per well and the concentrations of these compounds in these experiments were determined by titrating for their maximal effect (data not shown). The OCR of each well was normalized to the total protein in that well, as measured by the DC protein assay (BioRad, Hercules, CA).
Western blot analysis. LV tissue lysate (3 g protein) was separated on 8% [for sarco(endo)plasmic reticulum Ca 2ϩ -ATPase 2a (SERCA2a) and calsequestrin] or 12% [for phospholamban (PLN)] SDS-PAGE or 16.5% tricine gel [for sarcolipin (SLN)], transferred to a polyvinylidene difluoride membrane, and then incubated with antibodies to either SERCA2a (1:7,000), calsequestrin (1:5,000), PLN (1:5,000), or SLN (1:3,000) overnight at 4°C followed by an incubation with horseradish peroxidase-conjugated secondary antibodies. Membranes were incubated with Chemiluminescent Substrate (Pierce, Rockford, IL) and exposed to X-ray film. To assess protein levels of the voltage-dependant anion channel (VDAC), MnSOD, and citrate synthase, LV homogenates (25 g) were separated on 4 -15% SDS-PAGE gels, transferred to nitrocellulose membranes, incubated with their respective antibodies, and then incubated overnight at 4°C. Membranes were imaged using a charge-coupled device camera, and quantitations were done using AlphaView SA software (Protein Simple, San Jose, CA).
Statistics. Data are expressed as means Ϯ SE. Two-way ANOVA with a Student-Newman-Keuls post hoc test was used for all comparisons (unless otherwise specified) among sham, ACF, sham ϩ allopurinol, and ACF ϩ allopurinol. An unpaired two-tailed Student's t-test was used for comparison of SLN expression in ACF versus ACF ϩ allopurinol (see Fig. 6 ). An unpaired two-tailed Student's t-test was used for the comparison of ACF creatine kinase versus all other groups (see Fig. 7 ). In all cases, P values of Ͻ0.05 were considered statistically significant.
RESULTS

Effects of allopurinol on LV function over the 8-wk time course of ACF.
Serial echocardiography was performed at 2, 4, 6, and 8 wk in each group. Heart rate did not differ among sham and ACF-treated and untreated groups at all time points (Tables 1 and 2 ). LV end-diastolic dimension increased to a similar extent over the 8-wk time course in both treated and untreated ACF groups, achieving significance starting at the 4-wk time point vesus the sham group (Tables 1 and 2 and Fig. 1 ). In a similar fashion, LV end-systolic dimension also significantly increased over the 8-wk time course starting at 4 wk in untreated ACF versus sham rats. In contrast, in ACF ϩ allopurinol-treated rats, LV end-systolic dimension did not differ from either sham rats at 6 wk and was significantly lower than untreated ACF rats at the 8-wk time point. Indexes of LV systolic function, LV fractional shortening (LVFS) and the velocity of circumferential shortening (VCFr), in ACF rats fell below sham levels by 6 wk, with LVEF being decreased by 8 wk (Tables 1 and 2 ). However, LVEF, LVFS, and VCFr were all significantly increased in ACF ϩ allopurinol versus ACF rats by 4 wk, which persisted at 6 and 8 wk.
Effects of allopurinol on morphometrics and hemodynamics at 8 wk of ACF. Body weight was lower in both sham and ACF groups treated with allopurinol. The dose for allopurinol was chosen based on previous rat studies in which the dose ranged from 50 to 100 mg/day. One of the major side effects is gastrointestinal distress, which may have caused a decrease in weight due to a blunting of the appetite. Heart weight, LV weight, right ventricular weight, heart weight-to-body weight ratio, and lung weight were increased in both ACF groups compared with their respective sham group (Table 3) . Mean arterial pressure was increased with allopurinol treatment in sham ϩ allopurinol versus sham animals but was decreased in ACF ϩ allopurinol vs. ACF animals (P Ͻ 0.05 in both cases; Table 2 ). This change in mean arterial pressure occurred without affecting LV end-systolic pressure and was associated with an elevated LV end-diastolic pressure in both ACF groups. LV end-diastolic dimension, LV end-diastolic volume, LV end-diastolic wall thickness, and LV end-diastolic wall stress were increased in both ACF and ACF ϩ allopurinol groups versus their respective sham group (Table 2) . LV end-systolic dimension was markedly increased in ACF versus sham rats (P Ͻ 0.05) and was significantly improved in ACF ϩ allopurinol versus ACF rats (P Ͻ 0.05; Table 2) .
LVEF, LVFS, and LV VCFr, key indexes of LV systolic contractility, were depressed at 8 wk of ACF compared with sham animals (P Ͻ 0.05 in all cases). Treatment with allopurinol normalized each of these parameters in the ACF ϩ allopurinol group (Table 2 and Fig. 2 ). These data suggest that allopurinol protects systolic function in chronic VO.
LV Pressure-Volume Analysis
LV high-fidelity pressure was matched to simultaneous echocardiographic dimensions to generate LV pressure-volume loops. Data collected during a 3-to 5-s inferior vena cava occlusion yielded a set of LV pressure-volume loops at multiple LV loads. The LV pressure-volume area was increased 100% in ACF versus sham rats and significantly decreased in ACF ϩ allopurinol versus ACF rats (P Ͻ 0.05 in both cases). LV potential energy, a measure of the unused energy in the cardiac cycle, was also increased 100% in ACF versus sham rats and was decreased in ACF ϩ allopurinol versus ACF rats (Fig. 3) . LV efficiency (ratio between LV pressure-volume area and LV potential energy) was increased in sham ϩ allopurinol versus sham rats and in ACF ϩ allopurinol versus ACF rats (Fig. 3) . Analysis of the relatively load-independent LV maximal elastance demonstrated a decrease in LV contractility in ACF versus sham rats, which was significantly improved in ACF ϩ allopurinol rats (P Ͻ 0.05; Fig. 2D ). These data suggest that allopurinol treatment is associated with increased load-independent LV contractility and efficiency in chronic VO.
Allopurinol improves cardiomyocyte efficiency in chronic VO. To determine the bioenergetic response of the myocardium in response to a chronic volume load, LV cardiomyocytes were isolated and studied using the XF24. This XF24 measures the OCR in live, adherent cells, which is a reflection of mitochondrial function in the intact cell. Adult rat cardiomyocytes isolated from 8-wk sham and ACF Ϯ allopurinol rats and were seeded into V28 plates at 7,500 cells/well, and their OCRs were measured using the XF24. Parameters of mitochondrial function of the cardiomyocytes from each group were determined as shown in Fig. 4A . The maximal OCR of isolated cardiomyocytes in each group was measured after the injection of FCCP (1 M) in the XF24. FCCP is a protonophore that stimulates maximal O 2 consumption of the cells by uncoupling the mitochondria and diminishing membrane potential, which leads to the rapid consumption of O 2 without the production of ATP. As shown in Fig. 4B , basal, maximal, and nonmitochondrial OCR in all groups were not significantly different. However, the maximal OCR trended lower in sham and ACF ϩ allopurinol-treated rats compared with their respective untreated sham and ACF rats. To measure the nonmitochondrial OCR of the adult cardiomyocyte, antimycin A (10 M) and rotenone (1 M) were injected in the media simultaneously to inhibit the mitochondrial electron transport chain, resulting in a substantial decrease in the OCR. The remaining nonmitochondrial OCR can be attributed to extramitochondrial sources of O 2 consumption, such as XO and NAPDH oxidases. In the presence of allopurinol, there was a negative directional change in the nonmitochondrial OCR with allopurinol treatment in both sham and ACF rats, presumably by decreased O 2 consumption by the XO enzyme system. However, this did not approach statistical significance.
To ensure that the changes in the maximum OCR were not due to changes in mitochondrial number as a result of cardiac hypertrophy, we measured the protein levels of several mitochondrial proteins, such as VDAC, MnSOD, and citrate synthase, as indicators of overall mitochondrial content (Fig. 5) .
Consistent with our previous publications, VDAC protein levels were significantly increased in the ACF group compared with the sham group (Fig. 5, A and B) , suggesting that this could be a possible mechanism of increased mitochondrial Ca 2ϩ uptake (29, 39) , and this effect was not blunted by the addition of allopurinol to the ACF group. Since XO has been shown to be increased in VO, we decided to determine if the protein levels of MnSOD were altered as a compensatory mechanism to cope with increased levels of ROS, specifically O 2 ·Ϫ . As shown in Fig. 5 , A and C, only the allopurinol groups showed a slight, however, significant increase in MnSOD compared with the ACF group. This suggests that this may occur in a mechanism independent of XO and will require further investigation. Finally, to ascertain that the total mitochondrial population has not increased due to hypertrophic conditions of the heart, we examined the protein levels of citrate synthase as a marker of mitochondrial content. As shown in Fig. 5D groups. PLN, a regulatory protein that binds to SERCA2 and decreases its affinity for Ca 2ϩ , was also unchanged among all groups. SLN, another key regulator of the SERCA pump, which is normally expressed at undetectable levels in the ventricles, was significantly increased in ACF rats and was significantly deceased upon allopurinol treatment in ACF rats (Fig. 6) .
Creatine kinase activity in chronic 8-wk ACF. To determine the activity of creatine kinase, an enzyme involved in the transfer of high-energy phosphates during cardiomyocyte metabolism, we studied 8-wk LV tissue homogenates for maximal creatine kinase activity in sham and ACF Ϯ allopurinol rats. Creatine kinase activity was deceased in untreated ACF compared with sham rats and in sham and ACF ϩ allopurinol rats (Fig. 7) . Fig. 3 . Allo increases contractile efficiency and LV contractility in chronic VO. Rats were subject to either sham or ACF surgery with or without Allo (100 mg·kg Ϫ1 ·day Ϫ1 ) mixed in standard rat chow. Simultaneous high-fidelity pressure catheterization and echocardiography were performed at 8 wk. A 3 to 5-s transient inferior vena cava occlusion was performed, and a family of pressure-volume loops was generated and analyzed with computational software. The slope of the LV end-systolic pressure-volume relationship was decreased in ACF compared with sham animals and significantly improved in ACF ϩ Allo animals. LV PE, LV potential energy; LV PVA, LV pressure-volume area; XOi, XO inhibition. LV PE (A), LV PVA (B), LV Efficiency (C). *P Ͻ 0.05 vs. the sham group; #P Ͻ 0.05 vs. the ACF group.
DISCUSSION
The present study demonstrates XO inhibition improved load-dependent indexes of LV function by 4 wk and continued through 8 wk of VO of the ACF. At 8 wk, XO inhibition increased LV contractility and LV efficiency but did not improve LV remodeling or diastolic properties. We (18, 39) have previously demonstrated increased H 2 O 2 and O 2 ·Ϫ formation and XO activity in isolated cardiomyocytes after 24 h of ACF and increased XO activity after 3 h of stretch of isolated rat adult cardiomyocytes. A limitation of the present study is that we did not measure H 2 O 2 and O 2 ·Ϫ formation from isolated cardiomyocytes. As an alternative approach, we assessed protein carbonylation (marker of severe oxidative damage) and protein thiol oxidation using Bodipy-labeled N-ethylmaleimide and Bodipy-labeled iodoacetamide. There was a trend toward decreased Bodipy fluorescence (indicative of increased thiol oxidation/modification) in the ACF group compared with the sham group; however, there was a small but significant increase in MnSOD in allopurinol-treated sham and ACF rats. The original work of Marban and coworkers demonstrated that XO ϩ purine added to isolated right ventricular trabeculae reduces Ca 2ϩ sensitivity and force generation (17) and is improved by allopurinol (31) . Chronic VO creates an increase in cardiac workload and ATP turnover and purine catabolism in the face of an increase in LV XO activity. Taken together, an increase XO activity, which has been localized to the sarcoplasmic reticulum (27) in the cardiomyoctye, sets up a local increase O 2 ·Ϫ formation at the myofilaments, which is attenuated by direct XO inhibition as well as indirectly by an adaptive increase in MnSOD.
The improvement in LV contractile function with allopurinol is not paralleled by attenuation in LV dilatation, LV end-diastolic pressure/wall stress, or lung weight, and LV hypertrophy is not decreased despite a trend toward a lower mean arterial pressure. Other studies of acute (15, 38) or chronic (2, 34) XO inhibition in the dog with pacing tachycardia, myocardial infarction in the rabbit (41) and mouse (37) , and heart failure in the human (11) have shown little to no decrease in LV end-diastolic pressure or remodeling, despite augmented LV systolic function and the response to inotropic stimulation. In ACF rats, XO inhibition does not affect the loss of interstitial collagen (data not shown), which by itself can also decrease LV diastolic compliance due to interstitial edema and remodeling of myolaminar sheets (4) . Nevertheless, the separation of benefits on systolic and diastolic function with XO inhibition is of great interest in this and other models of heart failure, because the failure to improve symptoms and hospitalizations in the oxypurinol heart failure trial (23) may have been related to an inability of oxypurinol to improve diastolic function and pulmonary congestion. In the volume-overloaded heart, and more so in ischemic cardiomyopathy, this is particularly important because elevated LV diastolic wall stress has a negative impact on LV coronary perfusion pressure and the development of LV endocardial ischemia and fibrosis (12, 21, 40) .
At the 8 wk stage of VO, there is no decrease in maximum OCR in intact cardiomyocytes in the extracellular flux analyzer. In addition, protein levels of citrate synthase, which is a known marker of mitochondrial number, and several other mitochondrial markers, such as cytochrome c oxidase subunit I (inner membrane protein), VDAC (outer membrane protein), and MnSOD (matrix protein), are unchanged or increased across ACF and ACF treatment groups. This suggests no change in mitochondrial number in the face of a trend toward a decrease in cardiomyocyte OCR despite a significant increase in LV contractility. Most studies have reported the effects of cardiac hypertrophy associated with VO or pressure overload on subpopulations of mitochondria. It is of interest that interfibrillar mitochondria show a greater respiratory capacity than subsarcolem- mal mitochondria in healthy Spague-Dawley rat hearts but have greater depression of respiratory capacity and LV contractile dysfunction after 20 wk of pressure overload (35) . The use of the Seahorse extracellular flux analyzer provides the ability to localize the metabolic changes to intact cardiomyocytes excluding contamination from multiple cells types, maintaining mitochondrial localization in the cell, and obviating damage to mitochondria during isolation (14, 16, 32) . However, because the cells are not contracting, the maximum OCR does not provide information regarding ATP production, but the lack of sensitivity to oligomycin suggests that the capacity of the mitochondria in the unstressed condition to make ATP is not impaired by VO. Nevertheless, this question can only be accomplished by a stress of the intact heart with subsequent determinations of cardiac ATP levels.
There are several indirect off-target effects of allopurinol in VO that can partially contribute to the increase in LV contractility in addition to the increase in MnSOD. There was a small but significant 15% decrease in creatine kinase activity that was restored to normal by allopurinol. Creatine kinase reversibly and rapidly transfers a high-energy phosphoryl group between creatine phosphate and ATP, and the myofibrillar isoform of the creatine kinase enzyme is particularly sensitive to ROS (28) . Recently, Weiss and colleagues (22) have demonstrated a direct link between creatine kinase activity and LV contractile function in a transgenic mouse model. Allopurinol has also been shown to improve Ca 2ϩ homeostasis and oxidation/nitration of Ca 2ϩ -handling proteins in the tachypacing model in the dog (34) and in the spontaneously hypertensive rat (19) . In the present study, there was no change in SERCA protein levels and that of its regulator, PLN, at 8 wk, whereas 12-wk ACF has been reported to have a decrease in SERCA2 expression associated with decreased LV contractility and the response to Ca 2ϩ infusion in the isolated ACF heart (13, 36) . It is of interest that we found an increase in SLN in ACF LVs that was decreased by allopurinol. SLN is a key regulator of SERCA2 that is highly expressed in the atria and expressed at undetectable levels in the normal ventricle (3, 5-7, 9, 20) . Studies (3, 5-7, 9, 20) in transgenic mice have suggested that SLN functions as an inhibitor of SERCA by lowering its Ca 2ϩ affinity. We have recently found a similar ectopic expression of SLN and XO in LVs of patients with VO of isolated mitral regurgitation. The role of oxidative stress in mediating the decrease in creatine kinase activity and increase in SLN expression in the pathophysiology and progression to heart failure in VO requires further investigation.
In summary, the mechanical stimulus of a pure stretch/VO has multiple myocardial events including inflammation and matrix loss, cardiomyocyte and mitochondrial oxidative stress, and increased adrenergic drive (12, 17, 37) . The biological complexity of the pathogenic processes in a pure VO illustrates the challenges of targeting therapies that can prevent progressive cardiac remodeling and failure. In the present study, XO inhibition preserved LV systolic function but had no effect on mitochondrial respiration, LV diastolic function, or LV remodeling. We (18) have previously shown that cyclic stretch of cardiomyocytes increases XO activity, producing mitochondrial structural defects that are attenuated by the mitochondrial antioxidant MitoQ. Future studies involving the addition of mitochondria-targeted therapies, such as MitoQ, may elucidate the underlying mechanisms central to both bioenergetic and LV dysfunction in VO.
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